

# Yu-Gang Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/323032/publications.pdf>

Version: 2024-02-01

57  
papers

2,378  
citations

172457

29  
h-index

223800

46  
g-index

61  
all docs

61  
docs citations

61  
times ranked

3595  
citing authors

#	ARTICLE	IF	CITATIONS
1	In Situ Generation of Gold Nanoparticles on Bacteria-Derived Magnetosomes for Imaging-Guided Starving/Chemodynamic/Photothermal Synergistic Therapy against Cancer. <i>Advanced Functional Materials</i> , 2022, 32, .	14.9	24
2	Targeting ferroptosis suppresses osteocyte glucolipotoxicity and alleviates diabetic osteoporosis. <i>Bone Research</i> , 2022, 10, 26.	11.4	67
3	Shielding Ferritin with a Biomineralized Shell Enables Efficient Modulation of Tumor Microenvironment and Targeted Delivery of Diverse Therapeutic Agents. <i>Advanced Materials</i> , 2022, 34, e2107150.	21.0	24
4	FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway. <i>Molecular Oncology</i> , 2021, 15, 299-316.	4.6	47
5	APCCDC20-mediated degradation of PHD3 stabilizes HIF-1a and promotes tumorigenesis in hepatocellular carcinoma. <i>Cancer Letters</i> , 2021, 496, 144-155.	7.2	44
6	Hsa_circ_0007456 regulates the natural killer cell-mediated cytotoxicity toward hepatocellular carcinoma via the miR-6852-3p/ICAM-1 axis. <i>Cell Death and Disease</i> , 2021, 12, 94.	6.3	44
7	Mesenchymal Stem Cells-Derived Exosomes as Dexamethasone Delivery Vehicles for Autoimmune Hepatitis Therapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 650376.	4.1	21
8	Near-infrared light-triggered platelet arsenal for combined photothermal-immunotherapy against cancer. <i>Science Advances</i> , 2021, 7, .	10.3	57
9	lncRNA SNHG11 Promotes Gastric Cancer Progression by Activating the Wnt/ $\beta$ -Catenin Pathway and Oncogenic Autophagy. <i>Molecular Therapy</i> , 2021, 29, 1258-1278.	8.2	112
10	Ubc13 Promotes K63-Linked Polyubiquitination of NLRP3 to Activate Inflammasome. <i>Journal of Immunology</i> , 2021, 206, 2376-2385.	0.8	10
11	3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness. <i>Cell Death Discovery</i> , 2021, 7, 173.	4.7	10
12	Calcium channel TRPV6 promotes breast cancer metastasis by NFATC2IP. <i>Cancer Letters</i> , 2021, 519, 150-160.	7.2	22
13	In situ growth of nano-antioxidants on cellular vesicles for efficient reactive oxygen species elimination in acute inflammatory diseases. <i>Nano Today</i> , 2021, 40, 101282.	11.9	22
14	ERRF1 induces apoptosis of hepatocellular carcinoma cells in response to tryptophan deficiency. <i>Cell Death Discovery</i> , 2021, 7, 274.	4.7	10
15	MOFs-based nanoagent enables dual mitochondrial damage in synergistic antitumor therapy via oxidative stress and calcium overload. <i>Nature Communications</i> , 2021, 12, 6399.	12.8	95
16	Low-dose and same day use of polyethylene glycol improves image of video capsule endoscopy: A multicenter randomized clinical trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 634-640.	2.8	15
17	A 12-immune cell signature to predict relapse and guide chemotherapy for stage II colorectal cancer. <i>Aging</i> , 2020, 12, 18363-18383.	3.1	4
18	Targeting LncRNA EPIC1 to inhibit human colon cancer cell progression. <i>Aging</i> , 2020, 12, .	3.1	4

#	ARTICLE	IF	CITATIONS
19	Protective Effects of Oridonin on Acute Liver Injury via Impeding Posttranslational Modifications of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) in the Toll-Like Receptor 4 (TLR4) Signaling Pathway. Mediators of Inflammation, 2019, 2019, 1-11.	3.0	10
20	hsa_circ_0091570 acts as a ceRNA to suppress hepatocellular cancer progression by sponging hsa-miR-1307. Cancer Letters, 2019, 460, 128-138.	7.2	101
21	Long noncoding RNA FOXD3-AS1 promotes colon adenocarcinoma progression and functions as a competing endogenous RNA to regulate SIRT1 by sponging miR-135a-5p. Journal of Cellular Physiology, 2019, 234, 21889-21902.	4.1	45
22	Long noncoding RNA EPB41L4-AS2 inhibits hepatocellular carcinoma development by sponging miR-301a-5p and targeting FOXL1. Journal of Experimental and Clinical Cancer Research, 2019, 38, 153.	8.6	62
23	LncRNA DGCR5 represses the development of hepatocellular carcinoma by targeting the miR-346/KLF14 axis. Journal of Cellular Physiology, 2019, 234, 572-580.	4.1	48
24	T cell dysfunction in chronic hepatitis B infection and liver cancer: evidence from transcriptome analysis. Journal of Medical Genetics, 2019, 56, 22-28.	3.2	12
25	Exploration of Antigen Induced CaCO <sub>3</sub> Nanoparticles for Therapeutic Vaccine. Small, 2018, 14, e1704272.	10.0	55
26	Long non-coding RNA CASC15 regulates gastric cancer cell proliferation, migration and epithelial mesenchymal transition by targeting CDKN1A and ZEB1. Molecular Oncology, 2018, 12, 799-813.	4.6	84
27	Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma. Journal of Cellular Biochemistry, 2018, 119, 4711-4716.	2.6	135
28	Metformin Inhibited Growth, Invasion and Metastasis of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo. Cellular Physiology and Biochemistry, 2018, 51, 1276-1286.	1.6	14
29	Osteoinductivity and Antibacterial Properties of Strontium Ranelate-Loaded Poly(Lactic-co-Glycolic) Tj ETQq1 1 0.784314 rgBT /Overl... Pharmacology, 2018, 9, 368.	3.5	37
30	Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discovery, 2017, 3, 17004.	6.7	147
31	Strontium ranelate-loaded PLGA porous microspheres enhancing the osteogenesis of MC3T3-E1 cells. RSC Advances, 2017, 7, 24607-24615.	3.6	21
32	Bacterial inhibition potential of quaternised chitosan-coated VICRYL absorbable suture: An in vitro and in vivo study. Journal of Orthopaedic Translation, 2017, 8, 49-61.	3.9	29
33	Identification of a prognostic 5-Gene expression signature for gastric cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 619-629.	2.5	42
34	Targeting Osteocytes to Attenuate Early Breast Cancer Bone Metastasis by Theranostic Upconversion Nanoparticles with Responsive Plumbagin Release. ACS Nano, 2017, 11, 7259-7273.	14.6	100
35	Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget, 2017, 8, 90215-90224.	1.8	68
36	DDX11-AS1 as potential therapy targets for human hepatocellular carcinoma. Oncotarget, 2017, 8, 44195-44202.	1.8	21

#	ARTICLE	IF	CITATIONS
37	Downregulation of circulating exosomal miR-638 predicts poor prognosis in colon cancer patients. <i>Oncotarget</i> , 2017, 8, 72220-72226.	1.8	38
38	Oridonin ameliorates lipopolysaccharide/D-galactosamine-induced acute liver injury in mice via inhibition of apoptosis. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 4271-4279.	0.0	15
39	In vivo evaluation of the anti-infection potential of gentamicin-loaded nanotubes on titania implants. <i>International Journal of Nanomedicine</i> , 2016, 11, 2223.	6.7	31
40	Oridonin, a novel lysine acetyltransferases inhibitor, inhibits proliferation and induces apoptosis in gastric cancer cells through p53- and caspase-3-mediated mechanisms. <i>Oncotarget</i> , 2016, 7, 22623-22631.	1.8	52
41	The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg-positive chronic hepatitis B and nonalcoholic fatty liver disease. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2739-2744.	4.3	13
42	An updated dose-response meta-analysis of coffee consumption and liver cancer risk. <i>Scientific Reports</i> , 2016, 6, 37488.	3.3	30
43	Molecular Mechanism of Z <sup>1</sup> -Antitrypsin Deficiency. <i>Journal of Biological Chemistry</i> , 2016, 291, 15674-15686.	3.4	30
44	Effects of phased joint intervention on Rho/ROCK expression levels in patients with portal hypertension. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 1618-1624.	1.8	1
45	Anti-infective efficacy, cytocompatibility and biocompatibility of a 3D-printed osteoconductive composite scaffold functionalized with quaternized chitosan. <i>Acta Biomaterialia</i> , 2016, 46, 112-128.	8.3	128
46	Systemic transcriptome analysis of hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 13323-13331.	1.8	12
47	Cytocompatibility with osteogenic cells and enhanced in vivo anti-infection potential of quaternized chitosan-loaded titania nanotubes. <i>Bone Research</i> , 2016, 4, 16027.	11.4	54
48	Methylation-regulated miR-124-1 suppresses tumorigenesis in hepatocellular carcinoma by targeting CASC3. <i>Oncotarget</i> , 2016, 7, 26027-26041.	1.8	30
49	Salinomycin inhibits hepatocellular carcinoma cell invasion and migration through JNK/JunD pathway-mediated MMP9 expression. <i>Oncology Reports</i> , 2015, 33, 1057-1063.	2.6	13
50	Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation. <i>World Journal of Gastroenterology</i> , 2015, 21, 8326.	3.3	14
51	Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 1085-1098.	6.1	22
52	Macrophages derived from THP-1 promote the osteogenic differentiation of mesenchymal stem cells through the IL-23/IL-23R/Î²-catenin pathway. <i>Experimental Cell Research</i> , 2015, 339, 81-89.	2.6	23
53	CXCR1 knockdown improves the sensitivity of osteosarcoma to cisplatin. <i>Cancer Letters</i> , 2015, 369, 405-415.	7.2	36
54	Preparation, characterization, and in vitro osteoblast functions of a nano-hydroxyapatite/polyetheretherketone biocomposite as orthopedic implant material. <i>International Journal of Nanomedicine</i> , 2014, 9, 3949.	6.7	56

#	ARTICLE	IF	CITATIONS
55	Anti-miR-197 inhibits migration in HCC cells by targeting KAI 1/CD82. <i>Biochemical and Biophysical Research Communications</i> , 2014, 446, 541-548.	2.1	64
56	The Synergistic In Vitro and In Vivo Antitumor Effect of Combination Therapy with Salinomycin and 5-Fluorouracil against Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e97414.	2.5	43
57	Transdermal permeation of geniposide in the herbal complex liniment in vivo and in vitro. <i>International Journal of Pharmaceutics</i> , 2010, 392, 72-77.	5.2	8